1996•PubMedRequires access

NTZ qualifies for orphan drug status.

Author information unavailable

Abstract

Unimed Pharmaceuticals' nitazoxamide (NTZ) has been granted orphan drug status by the Food and Drug Administration (FDA). The designation gives the manufacturer seven years of exclusive rights to sell the drug. Nitazoxamide is used in the treatment of cryptosporidiosis, and is now in Phase II trials. The drug has proven to be safe and effective in more than 1,000 patients so far.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Orphan drug, Drug, Food and drug administration, Medicine, Pharmacology, Bioinformatics, Biology